Home Stocks RMTI Rockwell Medical Inc (NASDAQ: RMTI) Healthcare · Drug Manufacturers - Specialty & Generic
— —
Quote unavailable · Price data is temporarily unavailable.
The Quantellect read. The borrow fee is 0.77%. One active firm covers the stock as of Nov 19, 2026; one active firm with a target averages $20.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.
Relative valuation Lower multiples than peers P/S 0.4× vs peer median 2.0×
RMTI price chart Price — · As of —
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open —
Previous close —
Day range —
52-week range —
Volume —
Average volume (30 calendar days) —
Market cap —
P/E (TTM) —
Forward P/E —
EPS (TTM) —
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) —
Price history RMTI · NASDAQ · USD
Split-adjusted · volume in shares
Price history unavailable Retry
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score — · Q Score not available
How RMTI compares with its industry Against 83 other US-listed Drug Manufacturers - Specialty & Generic stocks
Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%
Points of cautionTrailing-year gross margin was 17.7%, with only 12% of 73 peers reporting a lower value.Peer median 57.7% · As of Nov 17, 2026 Valuation Lower multiples than peers
Metric RMTI Peer median
Price/sales 0.41× 1.99×
Higher than 18% of 78 peers
Forward P/E 19.53× 14.31×
Higher than 65% of 63 peers
Price/book 0.81× 1.92×
Higher than 28% of 82 peers
Profitability Profitability metrics are lower than most peers.
Metric RMTI Peer median
Growth Growth metrics are higher than most peers.
Metric RMTI Peer median
Quarterly sales growth, year over year 10.6% 4.8%
Higher than 63% of 83 peers
5-year sales growth rate — 7.6%
Not ranked: only 41 of 83 peers report it
Balance sheet Balance sheet metrics are lower than most peers.
Metric RMTI Peer median
Momentum Returns are lower than most peers.
Metric RMTI Peer median
1-year return −29.5% −12.1%
Higher than 41% of 74 peers
6-month return −25.6% −2.2%
Higher than 38% of 77 peers
3-month return −20.2% −7.8%
Higher than 42% of 78 peers
How to read this The dot marks where RMTI ranks among its peers on each metric, from lowest (left) to highest (right). The tick in the middle marks the peer median.
Green marks a rank in the top 10% of peers, amber the bottom 10%. Valuation and balance-sheet metrics stay neutral because a high rank there is not better or worse.
A metric is ranked only when enough peers report it. Peers exclude this company. Percentages count peers with a strictly lower value; equal values do not count.
Lowest Median Highest
Compared with 83 other US-listed Drug Manufacturers - Specialty & Generic stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 16, 2026
Upcoming events — · Upcoming events not available
Analyst consensus Insufficient coverage
0 Strong Buy
1 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 1 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $20.00
Average $20.00
High $20.00
As of Nov 19, 2026 across 1 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −0.40 −0.30 −0.20 −0.10 0.00 0.10 Q2 ’24 Q3 ’24 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q1 2026 −$0.03 −$0.04 —
Annual 2025 — −$0.15 —
Q3 2025 — −$0.05 —
Q2 2025 — −$0.05 —
Q1 2025 — −$0.04 —
Annual 2024 $0.02 −$0.03 —
Q3 2024 $0.10 $0.04 —
Q2 2024 −$0.35 $0.01 —
Smart-money activity In the last 60 days: 1 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.
Date Type Who Action Amount Source
Oct 1, 2026 Insider sell Strobeck Mark Sell $8.4K Form 4 Jan 2, 2026 Insider sell Hunter Heather Sell $2.4K Form 4 Nov 18, 2025 Insider sell COOPER JOHN G Sell $4.4K Form 4 Oct 1, 2025 Insider sell Hunter Heather Sell $3.4K Form 4 Oct 1, 2025 Insider sell Chole Timothy Sell $3.4K Form 4 Oct 1, 2025 Insider sell Strobeck Mark Sell $8.2K Form 4 Jul 1, 2025 Insider sell Chole Timothy Sell $2.4K Form 4 Jul 1, 2025 Insider sell Strobeck Mark Sell $5.7K Form 4 All smart-money activity →
News and press releases Year All 2026 Nov 12, 2026, 6:00 AM ET Nov 3, 2026, 6:00 AM ET All RMTI news → Company profile Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as
CEO Dr. Mark Strobeck Ph.D.
Headquarters Wixom, MI, United States
Employees 157
IPO date Jan 27, 1998
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic Q Score — · Q Score not available
Upcoming events — · Upcoming events not available
Analyst consensus Insufficient coverage
0 Strong Buy
1 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 1 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $20.00
Average $20.00
High $20.00
As of Nov 19, 2026 across 1 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −0.40 −0.30 −0.20 −0.10 0.00 0.10 Q2 ’24 Q3 ’24 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q1 2026 −$0.03 −$0.04 —
Annual 2025 — −$0.15 —
Q3 2025 — −$0.05 —
Q2 2025 — −$0.05 —
Q1 2025 — −$0.04 —
Annual 2024 $0.02 −$0.03 —
Q3 2024 $0.10 $0.04 —
Q2 2024 −$0.35 $0.01 —
Company profile Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as
CEO Dr. Mark Strobeck Ph.D.
Headquarters Wixom, MI, United States
Employees 157
IPO date Jan 27, 1998
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic